Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11387851 | 0.94 | PLA2G2A (0.72) | PLA2G2AL3MBTL1GAATP53TSHR | |
| SCHEMBL9402858 | 0.93 | PLA2G2A (0.75) | PLA2G2AL3MBTL1GAATP53TSHR | |
| SCHEMBL10497457 | 0.93 | PLA2G2A (0.75) | PLA2G2AL3MBTL1GAATP53TSHR | |
| SCHEMBL10498963 | 0.93 | PLA2G2A (0.75) | PLA2G2AL3MBTL1GAATP53TSHR | |
| SCHEMBL19565362 | 0.93 | PLA2G2A (0.75) | PLA2G2AL3MBTL1GAATP53TSHR | |
| SCHEMBL9702910 | 0.90 | PLA2G2A (0.56) | PLA2G2AL3MBTL1GAAALDH1A1MAPT | |
| SCHEMBL21110477 | 0.86 | KMT2A (0.54) | PLA2G2AL3MBTL1GAAALDH1A1MAPT | |
| SCHEMBL10830829 | 0.85 | PLA2G2A (0.86) | PLA2G2ATP53TSHRPLA2G4BRARB | |
| SCHEMBL17531343 | 0.85 | L3MBTL1 (0.53) | PLA2G2AL3MBTL1GAAALDH1A1MAPT | |
| SCHEMBL16471652 | 0.83 | L3MBTL1 (0.56) | PLA2G2AL3MBTL1GAATP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104974135-B | Targeting DNA has the Sai-Mi-Xi-Bu derivative containing benzene-naphthalene diimide structure of antitumor activity, pharmaceutical composition and its preparation method and application | 河北大学 | 2017-03-08 | — | — | CN | claimed |
| US-20170172945-A1 | METHODS OF TREATING BREAST CANCER | MITCHELL WOODS PHARMACEUTICALS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170172944-A1 | METHODS OF TREATING MELANOMA | MITCHELL WOODS PHARMACEUTICALS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170081276-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-03-23 | — | — | US | disclosed |
| CN-104974135-B | Targeting DNA has the Sai-Mi-Xi-Bu derivative containing benzene-naphthalene diimide structure of antitumor activity, pharmaceutical composition and its preparation method and application | 河北大学 | 2017-03-08 | — | — | CN | disclosed |
| US-20170007556-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-01-12 | — | — | US | disclosed |
| US-9522871-B2 | Preparation of (R,R)-fenoterol and (R,R)-or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160331702-A1 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2016-11-17 | — | — | US | disclosed |
| US-9492405-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-11-15 | — | — | US | disclosed |
| WO-2016144371-A1 | METHODS OF TREATING CANCER | MITCHELL WOODS PHARMACEUTICALS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2015153725-A2 | METHODS OF TREATING MELANOMA | MITCHELL WOODS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015153719-A2 | METHODS OF TREATING BREAST CANCER | MITCHELL WOODS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150157580-A1 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-06-11 | — | — | US | disclosed |
| WO-2015016729-A1 | UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2015-02-05 | — | — | WO | disclosed |
| US-20140187645-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130005799-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | SRI INTERNATIONAL | 2013-01-03 | — | — | US | disclosed |
| US-20120157543-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | Services, National Institutes of Health | 2012-06-21 | — | — | US | disclosed |
| US-20100168245-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-07-01 | — | — | US | disclosed |
| EP-0328669-A1 | CHALCONE DERIVATIVE COMPOUNDS | NIPPON OIL AND FATS COMPANY, LIMITED (JP) | 1989-08-23 | — | — | EP | disclosed |
| US-4245093-A | BY BROMINATION OF ALKANOYLOXYACETOPHENONES POST-TREATED WITH A TRIALKYL PHOSPHITE INHIBITS POLYBROMINATED BY-PRODUCTS | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1981-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150157580-A1 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES | CNR1, CNR2, GPR68 | PLA2G2A 443/4885L3MBTL1 2392/4885GAA 2543/4885 |
| US-20130005799-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | PLA2G2A 850/4885L3MBTL1 4159/4885GAA 3967/4885 |
| US-20120157543-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | PLA2G2A 1358/4885L3MBTL1 2823/4885GAA 3852/4885 |
| US-20170172945-A1 | METHODS OF TREATING BREAST CANCER | CNR2, ADRB2, CNR1 | PLA2G2A 595/4885L3MBTL1 3304/4885GAA 3840/4885 |
| US-20170081276-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | PLA2G2A 1358/4885L3MBTL1 2823/4885GAA 3852/4885 |
| US-20170172944-A1 | METHODS OF TREATING MELANOMA | CNR2, ADRB2, CNR1 | PLA2G2A 508/4885L3MBTL1 3073/4885GAA 3216/4885 |
| US-20100168245-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | PLA2G2A 1358/4885L3MBTL1 2823/4885GAA 3852/4885 |
| US-20140187645-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | PLA2G2A 1358/4885L3MBTL1 2823/4885GAA 3852/4885 |
| US-20160331702-A1 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES | CNR1, CNR2, GPR68 | PLA2G2A 443/4885L3MBTL1 2392/4885GAA 2543/4885 |
| US-20170007556-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | PLA2G2A 1024/4885L3MBTL1 4028/4885GAA 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.